Results 121 to 130 of about 825 (170)
Reactions Weekly, 2010 Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials ...
Peter J. Tyrer +81 more
core +7 more sources
Journal of Child and Adolescent Psychopharmacology, 2022 Objectives: To evaluate the short-term efficacy and safety of blonanserin in adolescents with schizophrenia.Methods: This 6-week multicenter, double-blind, randomized, placebo-controlled study investigated fixed-dose blonanserin (8 or 16 mg/day) in ...
Hiroshi Nakamura
exaly +2 more sources
Effect of dose timing in relation to food intake on systemic exposure to blonanserin [PDF]
European Journal of Clinical Pharmacology, 2010 Purpose Blonanserin is a novel potent dopamine D2 and serotonin 5-HT2 antagonist for treating schizophrenia. The aim of this study was to investigate prandial effects on systemic exposure to blonanserin in healthy volunteers, with particular attention ...
Junji Saruwatari +2 more
exaly +3 more sources
Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial [PDF]
Journal of Psychiatric Research, 2015 This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and
Fu-de Yang, Lehua Li
exaly +2 more sources